Arrhythmias & electrophysiologyRandomised controlled trial

Long-Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation

JAMAPublished

  • Randomised controlled trial
  • multicentre

Authors' conclusion

Among patients without documented atrial arrhythmia recurrence after catheter ablation for AF, discontinuing oral anticoagulant therapy resulted in a lower risk for the composite outcome of stroke, systemic embolism, and major bleeding vs continuing direct oral anticoagulant therapy.

Study context

Population
Adults (19–80 years) with ≥1 non-sex-related stroke risk factor (CHA2DS2-VASc) and no documented atrial arrhythmia recurrence for ≥1 year after catheter ablation for atrial fibrillation (AF); 18 hospitals in South Korea
Participants
840 adults
Comparison
Discontinuing vs continuing OAC after AF ablation
  • Discontinue oral anticoagulant therapyn = 417
  • Continue oral anticoagulant therapyn = 423reference
Primary endpoint
First occurrence of composite of:
  • Stroke
  • Systemic embolism
  • Major bleeding
Follow-up
2 years

Primary result

As reported in the abstract

Absolute difference

−1.9 percentage points

95% CI −3.5 to −0.3

P = 0.02

Events by treatment group

Discontinue OAC vs Continue OAC
absolute difference −1.9 percentage points (95% CI −3.5 to −0.3); P = 0.02

Secondary outcomes

OutcomeDiscontinue OACContinue OACabsolute difference (percentage points) (95% CI)
Ischemic stroke (2-year cumulative incidence)0.3%0.8%−0.5 (−1.6 to 0.6)

Safety

OutcomeDiscontinue OACContinue OACabsolute difference (percentage points) (95% CI)
Major bleeding0 events1.4%−1.4 (−2.6 to −0.2)

Original publication

Long-Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation. JAMA. Published 14 October 2025. doi:10.1001/jama.2025.14679

Summarised from the published abstract; every number is checked against it